Abstract
Aim: To investigate the frequency with which recommended treatment goals are met in high risk diabetic patients with conventional dose as opposed to high dose statin therapy and their different effects on lipoproteins and other cardiovascular disease (CVD) risk factors.Methods: Patients with type 2 diabetes and optimally treated hypertension were randomized to receive atorvastatin 10mg (n=59) or 80mg (n=60) daily. Data at baseline and after one year are reported.Results: Patients in the study were at high CVD risk (observed annual event rate of 4.8%). The non-high density lipoprotein cholesterol (non-HDL-C) therapeutic goal of
| Original language | English |
|---|---|
| Publication status | Published - 2015 |
| Event | EAS Congress 2015 - Duration: 22 Mar 2015 → 25 Mar 2015 |
Conference
| Conference | EAS Congress 2015 |
|---|---|
| Period | 22/03/15 → 25/03/15 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'A comparison of low and high dose atorvastatin on lipoproteins and inflammatory cytokines over one year in type 2 diabetes: the Protection against Nephropathy in Diabetes with Atorvastatin (PANDA) trial'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver